It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Most metabolic studies on mice are performed at room temperature, although under these conditions mice, unlike humans, spend considerable energy to maintain core temperature. Here, we characterize the impact of housing temperature on energy expenditure (EE), energy homeostasis and plasma concentrations of appetite- and glucoregulatory hormones in normal-weight and diet-induced obese (DIO) C57BL/6J mice fed chow or 45% high-fat-diet, respectively. Mice were housed for 33 days at 22, 25, 27.5, and 30 °C in an indirect-calorimetry-system. We show that energy expenditure increases linearly from 30 °C towards 22 °C and is ~30% higher at 22 °C in both mouse models. In normal-weight mice, food intake counter-balances EE. In contrast, DIO mice do not reduce food intake when EE is lowered. By end of study, mice at 30 °C, therefore, had higher body weight, fat mass and plasma glycerol and triglycerides than mice at 22 °C. Dysregulated counterbalancing in DIO mice may result from increased pleasure-based eating.
The impact of ambient housing temperature on the interaction of energy intake, energy expenditure and glycemic control in normal and diet-induced obese mice is examined.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Novo Nordisk A/S, Global Obesity and Liver Disease, Global Drug Discovery, Måløv, Denmark (GRID:grid.425956.9) (ISNI:0000 0004 0391 2646)
2 Novo Nordisk A/S, Global Obesity and Liver Disease, Global Drug Discovery, Måløv, Denmark (GRID:grid.425956.9) (ISNI:0000 0004 0391 2646); University of Copenhagen, Department of Veterinary and Animal Science, Faculty of Health and Medical Sciences, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
3 Novo Nordisk A/S, Global Obesity and Liver Disease, Global Drug Discovery, Måløv, Denmark (GRID:grid.425956.9) (ISNI:0000 0004 0391 2646); University of Copenhagen, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, DK-2200, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)